Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct 21;6(10):e486.
doi: 10.1038/bcj.2016.100.

Prevalence, incidence and survival of smoldering multiple myeloma in the United States

A Ravindran  1 , A C Bartley  2 , S J Holton  3 , W I Gonsalves  1 , P Kapoor  1 , M A Siddiqui  1 , S K Hashmi  1 , A L Marshall  1 , A A Ashrani  1 , A Dispenzieri  1 , R A Kyle  1 , S V Rajkumar  1 , R S Go  1   4
Affiliations

Prevalence, incidence and survival of smoldering multiple myeloma in the United States

A Ravindran et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Proportion of patients with SMM according to subgroups, including sociodemographic, geographic, treatment facility and co-morbidity. A/PI, Asian/Pacific Islander; NA, Native American; MW, Midwest; NE, Northeast; S, South; W, West. The level of education was classified by quartiles of percentage of adults in the patient's zip code who did not graduate from high school. Travel distance was calculated in miles as the distance between the patient's residence and treatment facility. P-value was <0.01 for all comparisons within each subgroup.
Figure 2
Figure 2
OS of multiple myeloma according to disease activity and era of diagnosis (a) and racial comparison of SMM survival (b). Survival time for smoldering myeloma started at 3 months from diagnosis, since a minimum of 120 days of follow-up was necessary to meet our definition of smoldering disease.
See this image and copyright information in PMC

References

    1. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15: e538–e548. - PubMed
    1. Dispenzieri A, Stewart AK, Chanan-Khan A, Rajkumar SV, Kyle RA, Fonseca R et al. Smoldering multiple myeloma requiring treatment: time for a new definition? Blood 2013; 122: 4172–4181. - PMC - PubMed
    1. Kristinsson SY, Holmberg E, Blimark C. Treatment for high-risk smoldering myeloma. New Engl J Med 2013; 369: 1762–1763. - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7–30. - PubMed
    1. Waxman AJ, Mink PJ, Devesa SS, Anderson WF, Weiss BM, Kristinsson SY et al. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood 2010; 116: 5501–5506. - PMC - PubMed

Publication types

LinkOut - more resources